Published in final edited form as:

Bioorg Med Chem. 2008 October 15; 16(20): 9295–9301. doi:10.1016/j.bmc.2008.09.002.

Synthesis of N-substituted 5-[2-(N-alkylamino)ethyl]dibenzo[c,h][1,6]-naphthyridines as novel topoisomerase I-targeting antitumor agents

Wei Feng^a, Mavurapu Satyanarayana^a, Liang Cheng^a, Angela Liu^b, Yuan-Chin Tsai^b, Leroy F. Liu^{b,c}, and Edmond J. LaVoie^{a,c,*}

^a Department of Pharmaceutical Chemistry, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

^b Department of Pharmacology, The University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, NJ 08854, USA

^c The Cancer Institute of New Jersey, New Brunswick, NJ 08901, USA

Abstract

Several *N*-alkyl and *N,N*-dialkyl 5*H*-8,9-dimethoxy-5-(2-aminoethyl)-2,3-methylenedioxydibenzo[*c,h*][1,6]naphthyridin-6-ones have been identified as topoisomerase I-targeting agents with potent antitumor activity. In the present study, the impact on biological activity of substitution of a trifluoromethyl, cyano, aminocarbonyl, or ethynyl group on a *N*-methyl substituent of *N,N*-dimethyl-, *N*-methyl-*N*-ethyl-, and *N*-methyl-*N*-isopropyl 5*H*-8,9-dimethoxy-5-(2-aminoethyl)-2,3-methylenedioxydibenzo[*c,h*][1,6]-naphthyridin-6-ones was assessed.

Keywords

Topoisomerase I; Cytotoxicity; Antitumor; MDA-MB-435; Structure-activity; Non-camptothecin

1. Introduction

Topoisomerases are ubiquitous enzymes that participate in processes such as DNA replication, repair, transcription, and recombination as well as chromosome condensation and segregation.^{1,2} Topoisomerase I (TOP1) is the target of several antitumor agents based upon their ability to stabilize the enzyme–DNA cleavage complex, which results in DNA damage and ultimately cell death.^{3–5} Several 5-(2-aminoethyl)dibenzo[*c,h*][1,6]naphthyridin-6-ones have been identified as topoisomerase I-targeting agents with potent antitumor activity.^{6,7} One of the more extensively studied of these non-camptothecin TOP1-targeting agents is 5*H*-8,9-dimethoxy-5-(2-*N,N*-dimethylaminoethyl)-2,3-methylenedioxydibenzo[*c,h*][1,6]-naphthyridin-6-one (ARC-111), **1** (Fig. 1).^{8,9} Analogs of ARC-111 with various 5-[2-(*N,N*-dialkylaminoethyl)] substituents have exhibited potent activity.⁹ Compounds **2** and **3** (Fig. 1) are among the tertiary alkylamine analogs that exhibit similar TOP1-targeting activity and cytotoxic activity in RPMI8402 cells to **1** (IC₅₀ values ranging from 2 to 6 nM).

The effect on biological activity of the addition of a trifluoromethyl, cyano, or ethynyl substituent on the *N*-methyl group of compounds related to ARC-111 was investigated. These

* Corresponding author. Tel.: +1 732 445 2674; fax: +1 732 445 6312. E-mail address: elavoie@rci.rutgers.edu (E.J. LaVoie).

studies were extended to examining the effect of an aminocarbonyl substituent on the *N*-methyl substituent of ARC-111 as well as the replacement of its 8,9-dimethoxy groups with 8,9-diethoxy substituents. These data provide further insight into the structure–activity associated with this family of potent non-camptothecin TOP1-targeting agents.

2. Results

2.1. Chemistry

The syntheses of compounds **4–6** were reported previously. The *N*-methyl-*N*-ethyl analog **2** of ARC-111 was prepared by reductive alkylation of **5**. Compounds **4**, **5**, and **6** were treated with trifluoromethanesulfonic acid 2,2,2-trifluoroethyl ester and diisopropylethylamine (DIEA) to afford **7**, **8**, and **9**, respectively (Scheme 1). Alkylation of **4**, **5**, and **6** using bromoacetonitrile provided compounds **10**, **11**, and **12**, respectively (Scheme 1). Conversion of **4**, **5**, and **6** to compounds **13**, **14**, and **15** were carried out in DMF at 80 °C using 3-bromopropyne and anhydrous potassium carbonate (Scheme 1).

Compound **16** was synthesized from **4** by reaction with bromoacetamide and potassium carbonate as outlined in Scheme 2.

The preparation of the diethoxy analog of **1** was performed as outlined in Scheme 3. Using similar methodology as previously described,⁹ 3,4-diethoxybenzoic acid was treated with iodine and silver trifluoroacetate in CHCl₃ to yield 4,5-diethoxy-2-iodobenzoic acid **17** in 60% yield. Conversion of **17** to its acid chloride **18** was carried out in anhydrous CH₂Cl₂ with oxalyl chloride. Without further purification **18** was added directly to the solution of appropriate 4-amino-6,7-methylenedioxyquinoline⁷ and TEA in CH₂Cl₂. Intramolecular Heck cyclization of iodobenzamide **20** was performed in refluxing DMF for 2 h to afford **21** in 34% yield, using Pd(OAc)₂, P(*o*-tolyl)₃, and Ag₂CO₃.

3. Results and discussion

The relative TOP1-targeting activities of the various *N*-substituted 5-[2-(*N*-alkylamino)ethyl] dibenzo[*c,h*][1,6]naphthyridines are listed in Table 1. The *N*-(2,2,2-trifluoroethyl) derivatives, **7–9**, did not exhibit appreciable TOP1-targeting activity. The basis for this loss in activity cannot be explained on the basis of steric factors in light of the potent TOP1-targeting activity observed for **1–3**.⁹ In contrast to these data, the cyano derivatives, **10–12**, were highly active TOP1-targeting agents with similar potency to ARC-111 and camptothecin. The *N*-methyl-*N*-propargyl derivative, **13**, and the *N*-methyl-*N*-acetamide derivative, **16**, also retained potent TOP1-targeting activity relative to that observed for **1–3**. The *N*-ethyl-*N*-propargyl derivative, **14**, and the *N*-isopropyl-*N*-propargyl derivative, **15** were much less active as TOP1-targeting agents. The diethoxy analog of ARC-111, **21**, exhibited a dramatic loss in TOP1-targeting activity.

Those derivatives with potent TOP1-targeting activity also exhibited the more pronounced cytotoxicity. The cytotoxicity of compounds **10–12** did not vary dramatically from one another with IC₅₀ values that ranged from 3 to 7 nM and 2 to 4 nM in RPMI8402 and P388, respectively. Compound **13** was less cytotoxic with IC₅₀ values that ranged from 2- to 20-fold higher than **10–12** in these cell lines. Compounds **14** and **15** had similar cytotoxicity in RPMI8402 to each other, but were 2- to 6-fold less cytotoxic than **13**. The aminocarbonyl derivative, **16**, exhibited similar cytotoxicity to **10–12**.

CPT-K5 cell line, a variant of RPMI8402 cells, and P388/CPT45 a variant of P388 have been used to investigate the role of TOP1 in the mechanism of cytotoxicity of suspect TOP1-targeting agents.^{10,11} Resistance to CPT-K5 cells is associated with its mutant form of the

enzyme TOP1 as well as its ability to express the efflux transporter BCRP.¹² Resistance to P388/CPT45, which has minimal expression of TOP1, is consistent with TOP1-targeting as the primary mechanism associated with cytotoxic activity. With the notable exception of **21**, these results suggest that TOP1-targeting is associated with cytotoxicity, even in the case of those derivatives with comparatively weak TOP1-targeting activity.

Data are provided in Table 2 on the relative cytotoxicity in the parent cell line, KB3-1, KBV-1, a variant that overexpresses the efflux transporter MDR1 (ABCB1/P-glycoprotein/PGY1/CD243), and KBH5.0, a variant that overexpresses BCRP (ABCG2/MXR/ABCP1). Differences in relative cytotoxicity between these variant cell lines and the parent cell line, KB3-1, may be indicative of a compound that is a substrate for an efflux transporter.^{13,14} Topotecan has been shown to be substrates for the MDR1 efflux transporter.¹³ Topotecan, as well as the active metabolite of irinotecan, SN-38, are resistant to tumor cells that express BCRP.^{15,16} In light of their 7-fold difference in IC₅₀ values between KB3-1 cells and KBV-1 cells, the data suggest that **10–12** and **16** are substrates for MDR1. While not among the more potent cytotoxic agents, **13** does not appear to be a substrate for either MDR1 or BCRP. It is of interest to note that, of the compounds evaluated; only **16** appears to be a substrate for BCRP.

Compounds **8** and **10–16** were evaluated for antitumor activity in vivo in athymic nude mice with MDA-MB-435 human tumor xenografts. The results of this bioassay are outlined in Table 3 and are illustrated in Figures 2–4.

Figure 2 clearly illustrates that the *N*-methyl-*N*-cyanomethyl analog **10** is less active than the *N*-methyl-*N*-propargyl **13** or *N*-methyl-*N*-acetamide **16** at their maximally tolerated doses. The *N*-methyl-*N*-2,2,2-trifluoroethyl analog **8** was also less efficacious than the *N*-ethyl-*N*-cyanomethyl analog **11** or the *N*-ethyl-*N*-propargyl derivative **14** as illustrated in Figure 3. While in vitro studies did indicate that **14** and **15** were less cytotoxic than their structurally related cyano derivatives, **11** and **12**, this did result in notable differences in their antitumor activity in vivo. Both **11** and **14** had similar antitumor activity, but were less potent and effective than ARC-111 in this bioassay. The *N*-isopropyl-*N*-cyanomethyl and the *N*-isopropyl-*N*-propargyl derivatives, **12** and **15**, respectively, also had similar antitumor activity (Fig. 4). Both of these derivatives, however, appear from these in vivo studies to be less potent and less efficacious than ARC-111 (Table 3).

These comparative studies did not result in the identification of an analog of ARC-111 with comparable in vivo potency and efficacy. The presence of electron-withdrawing substituents on the *N*-methyl substituents of these various analogs of compounds **1–3** did negatively affect the relative ease with which they could be formulated for injection. The decreased basicity of these derivatives lessened the solubility of their citrate salts and may have also impacted their absorption and distribution. Further studies are in process to assess the influence of other more polar substituents on the amino group of the 5-(2-aminoethyl) substituent of ARC-111 and related compounds.

4. Experimental

Melting points were determined with either a Thomas-Hoover Unimelt or Meltemp capillary melting point apparatus. Column chromatography refers to flash chromatography conducted on Sil-iTech 32–63 μ m, (ICN Biomedicals, Eschwege, Germany) using the solvent systems indicated. Proton (¹H NMR) and carbon (¹³C NMR) nuclear magnetic resonance were recorded on a Varian Gemini-2000 Fourier Transform spectrometer. Infrared spectral data were obtained using a Thermo-Nicolet Avatar 360 Fourier transform spectrophotometer and are reported in cm⁻¹. NMR spectra (200 MHz ¹H and 50 MHz ¹³C) were recorded in the deuterated solvent indicated with chemical shifts reported in δ units downfield from tetramethylsilane (TMS). Coupling constants are reported in hertz (Hz). Mass spectra were obtained from Washington

University Resource for Biomedical and Bio-organic Mass Spectrometry within the Department of Chemistry at Washington University, St. Louis, MO, USA. All starting materials and reagents were purchased from Aldrich. Solvents were purchased from Fisher Scientific, and were A.C.S. grade or HPLC grade. Methylene chloride was freshly distilled from calcium hydride. All other solvents were used as provided without further purification. Compounds **5–7** were prepared as previously described.⁹ Methods for the preparation of intermediate **19** have also been previously reported.⁷ Trifluoromethanesulfonic acid 2,2,2-trifluoroethyl ester was purchased from TCI America (Portland, OR).

4.1. 2,3-Methylenedioxy-8,9-dimethoxy-5-[*N*-ethyl-*N*-methyl aminoethyl]dibenzo[*c,h*][1,6]naphthyridin-6-one (**2**)

A mixture of **5** (150 mg, 0.37 mmol), acetaldehyde (0.2 mL, 3.38 mmol), and sodium cyanoborohydride (78 mg, 1.1 mmol) in ethanol (15 mL) was heated to 75 °C in a sealed tube for 6 h. The mixture was filtered and the filtrate was evaporated. The residue was partitioned between chloroform (50 mL) and 10% NaOH (30 mL), and the aqueous phase was extracted with chloroform (2× 50 mL). The combined organic phases were evaporated and chromatographed through a short column of silica eluting with 97:3 chloroform/methanol, to provide 89 mg (55% yield); mp 251–253 °C; IR (neat) 1650; ¹H NMR (CDCl₃): δ 1.01 (t, *J* = 7.4, 3H), 2.27 (s, 3H), 2.46 (q, *J* = 7.4, 2H), 3.01 (t, *J* = 7, 2H), 4.04 (s, 3H), 4.10 (s, 3H), 4.60 (t, *J* = 7, 2H), 6.15 (s, 2H); 7.44 (s, 1H), 7.65 (s, 1H), 7.87 (s, 1H), 7.92 (s, 1H), 9.34 (s, 1H), ¹³C NMR (CDCl₃ + CD₃OD) δ 11.1, 40.9, 47.8, 50.8, 53.9, 55.1, 55.3, 100.0, 101.0, 101.3, 105.2, 107.6, 110.0, 113.7, 118.1, 126.5, 139.9, 142.1, 145.6, 146.8, 149.1, 149.3, 153.3, 163.2; HRMS (*M*⁺+H) Calcd for C₂₄H₂₅N₃O₅H: 436.1872; found: 436.1874.

4.2. General procedure for the preparation of 2,3-methylenedioxy-8,9-dimethoxy-5-[*N*-alkyl-*N*-(2,2,2-trifluoro ethyl)aminoethyl]dibenzo[*c,h*][1,6]naphthyridin-6-ones (**7–9**)

To a mixture of 2,3-methylenedioxy-8,9-dimethoxy-5-[2-alkylaminoethyl]dibenzo[*c,h*]-[1,6]naphthyridin-6-one (1.0 mmol equiv) in DMF (8 mL per mmol equiv) was added DIEA (20.0 mmol equiv) and 2,2,2-trifluoroethyl trifluoromethanesulfonate (5.0 mmol equiv) at room temperature. The resulting reaction mixture was heated to 80 °C with stirring. The reaction mixture was allowed to cool to room temperature, and then diluted with CHCl₃. The CHCl₃ solution was washed with water, then brine, dried over Na₂SO₄, and concentrated under reduced pressure. The residue was chromatographed on silica gel using dichloromethane:methanol.

4.2.1. 2,3-Methylenedioxy-8,9-dimethoxy-5-[*N*-methyl-*N*-(2,2,2-trifluoroethyl)aminoethyl]dibenzo[*c,h*][1,6]naphthyridin-6-one (7**)**—Prepared from **4** (50 mg, 0.12 mmol); (43% yield); reaction time 4 h; mp 237–239 °C; IR (neat): 1647; ¹H NMR (CDCl₃) δ 2.43 (s, 3H), 3.04 (q, 2H, *J* = 9.4), 3.22 (t, 2H, *J* = 6.8), 4.04 (s, 3H), 4.11 (s, 3H), 4.62 (t, 2H, *J* = 6.8), 6.16 (s, 2H), 7.44 (s, 1H), 7.64 (s, 1H), 7.70 (s, 1H), 7.84 (s, 1H), 9.33 (s, 1H); ¹³C NMR (CDCl₃) δ 42.2, 47.9, 55.2, 55.4, 55.4, 57.3 (q, *J* = 30.8), 99.8, 101.0, 101.3, 106.2, 107.7, 110.9, 113.8, 118.3, 124.6 (q, *J* = 279.6), 126.7, 140.0, 142.5, 146.2, 146.8, 149.0, 149.3, 153.2, 163.3; HRMS *m/z* Calcd for C₂₅H₂₇N₃O₅H: 490.1590; found: 490.1567.

4.2.2. 2,3-Methylenedioxy-8,9-dimethoxy-5-[*N*-ethyl-*N*-(2,2,2-trifluoroethyl)aminoethyl]dibenzo[*c,h*][1,6]naphthyridin-6-one (8**)**—Prepared from **5** (100 mg, 0.20 mmol); (31% yield); reaction time 7 h; mp 246–248 °C; IR (neat): 1644; ¹H NMR (CDCl₃) δ 0.98 (t, 3H, *J* = 7.0), 2.72 (q, 2H, *J* = 7.0), 3.11 (q, 2H, *J* = 9.6), 3.26 (t, 2H, *J* = 7.4), 4.05 (s, 3H), 4.12 (s, 3H), 4.60 (t, 2H, *J* = 7.4), 6.17 (s, 2H), 7.44 (s, 1H), 7.64 (s, 1H), 7.70 (s, 1H), 7.85 (s, 1H), 9.34 (s, 1H); ¹³C NMR (CDCl₃) δ 11.1, 48.1, 48.2, 52.1, 53.8 (q, *J* = 30.4), 55.4, 55.4, 99.8, 100.9, 101.4, 106.2, 107.7, 110.8, 113.7, 118.3, 124.7 (q, *J* = 279.4), 126.7, 139.8,

142.5, 146.3, 146.8, 149.0, 149.3, 153.2, 163.3; HRMS m/z Calcd for $C_{25}H_{24}F_3N_3O_5H$: 504.1746; found: 504.1748.

4.2.3. 2,3-Methylenedioxy-8,9-dimethoxy-5-[*N*-isopropyl-*N*-(2,2,2-trifluoroethyl)aminoethyl]dibenzo[*c,h*][1,6]naphthyridin-6-one (9)—Prepared from **6** (50 mg, 0.12 mmol); (52% yield); reaction time 7 h; mp 258–261 °C; IR (neat): 1650; 1H NMR ($CDCl_3$) δ 1.01 (d, 6H, J = 6.6), 3.0 (m, 1H), 3.07 (q, 2H, J = 9.6), 3.24 (t, 2H, J = 7.6), 4.05 (s, 3H), 4.12 (s, 3H), 4.58 (t, 2H, J = 7.6), 6.17 (s, 2H), 7.46 (s, 1H), 7.67 (s, 1H), 7.73 (s, 1H), 7.87 (s, 1H), 9.37 (s, 1H); ^{13}C NMR ($CDCl_3$) δ 17.4, 48.9, 49.2, 51.3 (q, J = 31.9), 51.8, 55.4, 55.4, 99.8, 100.9, 101.3, 106.2, 107.7, 110.8, 113.8, 118.3, 124.6 (q, J = 279.6), 126.8, 139.9, 142.5, 146.2, 146.8, 149.0, 149.3, 153.2, 163.3; HRMS m/z Calcd for $C_{26}H_{26}F_3N_3O_5H$: 518.1903; found: 518.1903.

4.3. General procedure for the preparation of 2,3-methylenedioxy-8,9-dimethoxy-5-[*N*-alkyl-*N*-cyanomethyl aminoethyl]dibenzo[*c,h*][1,6]naphthyridin-6-ones (10–12)

To a solution of 2,3-methylenedioxy-8,9-dimethoxy-5-[2-alkylaminoethyl]dibenzo[*c,h*][1,6]naphthyridin-6-one (1.0 mmol equiv) in DMF (8 mL per mmol equiv) was added potassium carbonate (20.0 mmol equiv) and bromoacetonitrile (3.0 mmol equiv) at room temperature. The resulting reaction mixture was heated at 75 °C with stirring. The reaction mixture was allowed to cool to room temperature, and then diluted with $CHCl_3$. The $CHCl_3$ solution was washed with water, and then brine, dried over Na_2SO_4 , filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography using dichloromethane: methanol.

4.3.1. 2,3-Methylenedioxy-8,9-dimethoxy-5-[*N*-cyanomethyl-*N*-methyllaminoethyl]dibenzo[*c,h*][1,6]naphthyridin-6-one (10)—Prepared from **4** (50 mg, 0.12 mmol); (64% yield); reaction time 35 min; mp 235–236 °C; IR (neat): 2239, 1639; 1H NMR ($CDCl_3$): δ 2.32 (s, 3H), 3.07 (t, 2H, J = 6.6 Hz), 3.43 (s, 2H), 4.08 (s, 3H), 4.14 (s, 3H), 4.70 (t, 2H, J = 6.6 Hz), 6.20 (s, 2H), 7.50 (s, 1H), 7.66 (s, 1H), 7.69 (s, 1H), 7.89 (s, 1H), 9.39 (s, 1H); ^{13}C NMR ($CDCl_3$ + CD_3OD): δ 35.9, 40.8, 44.7, 53.0, 55.4, 99.4, 101.1, 105.3, 107.7, 111.1, 113.7, 116.1, 118.1, 126.3, 140.0, 142.2, 145.5, 147.0, 149.2, 149.4, 153.2, 163.5; HRMS m/z Calcd for $C_{24}H_{22}N_4O_5H$ 447.1668; found: 447.1660.

4.3.2. 2,3-Methylenedioxy-8,9-dimethoxy-5-[*N*-cyanomethyl-*N*-ethylaminoethyl]dibenzo[*c,h*][1,6]naphthyridin-6-one (11)—Prepared from **5** (100 mg, 0.24 mmol); (80% yield); reaction time 40 min; mp 226–227 °C; IR (neat): 2285, 1634; 1H NMR ($CDCl_3$): δ 0.83 (t, 3H, J = 7.2), 2.49 (q, 2H, J = 7.2), 3.05 (t, 2H, J = 6.6), 3.42 (s, 2H), 4.08 (s, 3H), 4.14 (s, 3H), 4.72 (t, 2H, J = 6.6), 6.20 (s, 2H), 7.51 (s, 1H), 7.67 (s, 1H), 7.68 (s, 1H), 7.89 (s, 1H), 9.38 (s, 1H); ^{13}C NMR ($CDCl_3$ + CD_3OD): δ 11.4, 40.8, 47.2, 47.3, 50.9, 55.2, 55.4, 99.4, 100.0, 101.6, 104.9, 107.6, 111.2, 113.7, 114.0, 118.0, 126.2, 140.1, 141.7, 144.8, 147.0, 149.4, 153.3, 163.3; HRMS m/z Calcd for $C_{25}H_{24}N_4O_5H$ 461.1825; found: 461.1826.

4.3.3. 2,3-Methylenedioxy-8,9-dimethoxy-5-[*N*-cyanomethyl-*N*-isopropylaminoethyl]dibenzo[*c,h*][1,6]naphthyridin-6-one (12)—Prepared from **6** (100 mg, 0.23 mmol); (49% yield); reaction time 90 min; mp 219–220 °C; IR (neat): 2287, 1644; 1H NMR ($CDCl_3$): δ 0.90 (d, 6H, J = 6.6), 2.78 (m, 1H), 3.12 (t, 2H, J = 6.6), 3.41 (s, 2H), 4.07 (s, 3H), 4.14 (s, 3H), 4.68 (t, 2H, J = 6.6), 6.19 (s, 2H), 7.48 (s, 1H), 7.66 (s, 2H), 7.88 (s, 1H), 9.36 (s, 1H); ^{13}C NMR ($CDCl_3$): δ 18.3, 37.7, 47.3, 47.6, 52.4, 55.4, 99.4, 100.9, 101.4, 105.7, 107.9, 111.1, 113.7, 116.1, 118.3, 126.3, 140.0, 142.0, 145.5, 146.9, 149.2, 149.4, 153.2, 163.3; HRMS m/z Calcd for $C_{26}H_{26}N_4O_5H$ 475.1981; found: 475.1982.

4.4. General procedure for the preparation of 2,3-methylenedioxy-8,9-dimethoxy-5-[*N*-alkyl-*N*-(prop-2-ynyl)aminoethyl]dibenzo[*c,h*][1,6]naphthyridin-6-ones (13–15)

To a mixture of 2,3-methylenedioxy-8,9-dimethoxy-5-[2-alkylaminoethyl]dibenzo[*c,h*][1,6]naphthyridin-6-one (1.0 mmol equiv) in DMF (8 mL per mmol equiv) was added potassium carbonate (20.0 mmol equiv) and 3-bromopropyne (3.0 mmol equiv) at room temperature. The resulting reaction mixture was heated up to 80 °C with stirring. The reaction mixture was allowed to cool to room temperature, and then diluted with CHCl₃. The CHCl₃ solution was washed with water, then brine, dried over Na₂SO₄, and concentrated under reduced pressure. The residue was chromatographed on silica gel using dichloromethane:methanol.

4.4.1. 2,3-Methylenedioxy-8,9-dimethoxy-5-[*N*-methyl-*N*-(prop-2-ynyl)aminoethyl]dibenzo[*c,h*][1,6]naphthyridin-6-one (13)

—Prepared from **4** (100 mg, 0.25 mmol); (65% yield); reaction time 30 min; mp 239–241 °C; IR (neat): 1648; ¹H NMR (CDCl₃) δ 2.22 (t, 1H, *J* = 2.2), 2.34 (s, 1H), 3.09 (t, 2H, *J* = 6.6), 3.30 (d, 2H, *J* = 2.2), 4.04 (s, 3H), 4.11 (s, 3H), 4.61 (t, 2H, *J* = 6.6), 6.16 (s, 2H), 7.42 (s, 1H), 7.65 (s, 1H), 7.77 (s, 1H), 7.85 (s, 1H), 9.31 (s, 1H); ¹³C NMR (CDCl₃) δ 42.0, 46.4, 48.9, 54.0, 56.3, 56.3, 73.4, 78.6, 101.0, 102.0, 102.2, 107.1, 108.8, 111.7, 114.8, 119.3, 127.6, 140.9, 143.4, 147.2, 147.7, 149.9, 150.2, 154.1, 164.1; HRMS *m/z* Calcd for C₂₅H₂₃N₃O₅H: 446.1716; found: 446.1716.

4.4.2. 2,3-Methylenedioxy-8,9-dimethoxy-5-[*N*-ethyl-*N*-(prop-2-ynyl)aminoethyl]dibenzo[*c,h*][1,6]naphthyridin-6-one (14)

—Prepared from **5** (100 mg, 0.20 mmol); (64% yield); reaction time 60 min; mp 227–229 °C; IR (neat): 1648; ¹H NMR (CDCl₃) δ 0.95 (t, 3H, *J* = 7.4), 2.18 (t, 1H, *J* = 2.2), 2.56 (q, 2H, *J* = 7.4), 3.12 (t, 2H, *J* = 7.0), 3.33 (d, 2H, *J* = 2.2), 4.04 (s, 3H), 4.10 (s, 3H), 4.56 (t, 2H, *J* = 7.0), 6.15 (s, 2H), 7.41 (s, 1H), 7.59 (s, 1H), 7.78 (s, 1H), 7.84 (s, 1H), 9.28 (s, 1H); ¹³C NMR (CDCl₃) δ 12.7, 42.1, 47.9, 49.1, 51.6, 56.3, 56.3, 73.0, 78.7, 101.1, 101.9, 102.2, 107.0, 108.8, 111.6, 114.7, 119.3, 127.4, 140.8, 143.3, 147.1, 147.6, 149.8, 150.2, 154.0, 164.0; HRMS *m/z* Calcd for C₂₆H₂₅N₃O₅H: 460.1872; found: 460.1890.

4.4.3. 2,3-Methylenedioxy-8,9-dimethoxy-5-[*N*-isopropyl-*N*-(prop-2-ynyl)aminoethyl]dibenzo[*c,h*][1,6]naphthyridin-6-one (15)

—Prepared from **6** (100 mg, 0.23 mmol); (58% yield); reaction time 60 min; mp 217–219 °C; IR (neat): 1649; ¹H NMR (CDCl₃) δ 0.98 (t, 6H, *J* = 6.6), 2.13 (t, 1H, *J* = 1.8), 2.93 (m, 1H), 3.16 (t, 2H, *J* = 7.0), 3.33 (d, 2H, *J* = 1.8), 4.04 (s, 3H), 4.11 (s, 3H), 4.58 (t, 2H, *J* = 7.0), 6.15 (s, 2H), 7.41 (s, 1H), 7.60 (s, 1H), 7.80 (s, 1H), 7.85 (s, 1H), 9.29 (s, 1H); ¹³C NMR (CDCl₃) δ 19.5, 39.6, 48.1, 49.7, 52.4, 56.3, 56.3, 72.4, 80.8, 101.2, 101.9, 102.2, 107.0, 108.8, 111.7, 114.8, 119.4, 127.6, 141.0, 143.4, 147.1, 147.6, 149.8, 150.2, 154.1, 164.1; HRMS *m/z* Calcd for C₂₇H₂₈N₃O₅H: 474.2029; found: 474.2031.

4.5. 2,3-Methylenedioxy-8,9-dimethoxy-5-[*N*-(2-amino-2-oxoethyl)-*N*-methylaminoethyl]dibenzo[*c,h*][1,6]naphthyridin-6-ones (16)

Prepared from **4** (150 mg, 0.37 mmol) and bromoacetamide (56 mg, 0.41 mmol); reaction time 40 min; (47% yield); mp 228–229 °C; IR (neat): 3423, 1671, 1647; ¹H NMR (CDCl₃ + CD₃OD): δ 2.17 (s, 3H), 2.93 (s, 2H), 3.00 (t, 2H, *J* = 6.6 Hz), 4.00 (s, 3H), 4.08 (s, 3H), 4.14 (s, 3H), 4.63 (t, 2H, *J* = 6.6 Hz), 6.14 (s, 2H), 7.39 (s, 1H), 7.63 (s, 1H), 7.65 (s, 1H), 7.80 (s, 1H), 9.30 (s, 1H); ¹³C NMR (CDCl₃ + CD₃OD): δ 41.9, 47.2, 47.6, 55.2, 60.2, 99.4, 101.1, 101.5, 105.2, 107.6, 111.5, 113.7, 116.0, 118.0, 126.3, 141.0, 142.0, 144.8, 147.0, 149.5, 153.4, 163.3, 171.4; HRMS *m/z* Calcd for C₂₄H₂₄N₄O₆H 465.1774; found: 465.1791.

4.6. 4,5-Diethoxy-2-iodobenzoic acid (**17**)

To a suspension of 3,4-diethoxybenzoic acid (1.8 g, 8.6 mmol) and silver trifluoroacetate (2.0 g, 9.02 mmol) in 15 mL CHCl_3 was added I_2 (2.29 g, 9.0 mmol) portionwise at 0 °C. The resulting reaction mixture was warmed up to room temperature with stirring overnight. The reaction mixture was quenched with 10 mL water. The organic layer was washed with satd $\text{Na}_2\text{S}_2\text{O}_3$ solution (2 × 10 mL), brine (1 × 10 mL), dried over Na_2SO_4 , and concentrated under reduced pressure. The residue was chromatographed on silica gel using ethyl acetate/hexanes (1:1), yielding 1.4g in 50% yield as a light brown solid; mp 195–197 °C; IR (neat): 1694; ^1H NMR (CDCl_3) δ 1.49 (m, 6H), 4.14 (m, 4H), 7.44 (s, 1H), 7.63 (s, 1H), 9.2 (s, 1H); ^{13}C NMR (CDCl_3) δ 13.7, 13.7, 63.8, 64.0, 84.7, 115.4, 124.4, 124.4, 147.2, 151.6, 170.5; HRMS m/z Calcd for $\text{C}_{11}\text{H}_{13}\text{IO}_4$: 334.9775; found: 334.9784.

4.7. *N*-([1,3]Dioxolo[4,5-*g*]quinolin-8-yl)-*N*-(2-(dimethylamino)ethyl)-4,5-diethoxy-2-iodobenzamide (**20**)

Oxalyl chloride (1.3 mL, 11.3 mmol) was added to a mixture of 2-iodo-4,5-diethoxybenzoic acid (1.95 g, 5.7 mmol) in methylene chloride (40 mL), and the mixture was heated to reflux under nitrogen with stirring for 4 h. The mixture was concentrated to dryness under vacuum to provide crude **18**. The acid chloride was used without purification and redissolved in 40 mL of methylene chloride, and a solution of **19**⁷ (1.24 g, 4.78 mmol) added, then triethylamine (2.0 mL, 27 mmol) was added. The mixture was heated to reflux with stirring for 16 h and was then cooled to room temperature. The mixture was washed with saturated NaHCO_3 (3 × 100 mL) and extracted into dilute aqueous HCl (3 × 100 mL). The combined aqueous phases were washed with chloroform (2 × 100 mL), basified (30% NaOH), and extracted with chloroform (3 × 100 mL). The combined organic layers were washed with brine (100 mL), dried (Mg_2SO_4), and evaporated, yielding 2.6 g in 94% yield as a light brown sticky glue; IR (neat): 1654. ^1H NMR (CDCl_3) δ 1.00 (t, 3H, $J = 7.0$), 1.28 (t, 3H, $J = 7.0$), 2.19 (s, 6H), 2.55 (m, 2H), 3.25 (m, 1H), 3.52 (q, 2H, $J = 7.0$), 3.85 (q, 2H, $J = 7.0$), 4.44 (m, 1H), 6.09 (m, 2H), 6.31 (s, 1H), 6.97 (s, 1H), 7.25 (d, 1H, $J = 4.6$), 7.29 (s, 1H), 7.35 (s, 1H), 7.25 (d, 1H, $J = 4.6$); ^{13}C NMR (CDCl_3) δ 14.3, 14.6, 45.6, 46.9, 56.6, 64.3, 64.6, 82.8, 98.5, 102.2, 106.7, 112.3, 120.2, 123.0, 123.2, 133.6, 146.0, 147.5, 148.3, 148.4, 149.0, 149.6, 151.0, 170.0; HRMS m/z Calcd for $\text{C}_{25}\text{H}_{28}\text{IO}_5\text{N}_3$: 578.1146; 2029; found: 578.1149.

4.8. 2,3-Methylenedioxy-8,9-diethoxy-5-(2-*N,N*-dimethylaminoethyl)dibenzo[*c,h*][1,6]naphthyridin-6-one (**21**)

A mixture of **19** (1.5 g, 2.6 mmol), $\text{Pd}(\text{OAc})_2$ (117 mg, 0.52 mmol), $\text{P}(o\text{-tolyl})_3$ (390 mg, 1.3 mmol), and Ag_2CO_3 (1.43 g, 5.2 mmol) in dimethylformamide (DMF) (35 mL) was heated to reflux with stirring for 30 min. The reaction mixture was cooled, diluted with chloroform, and filtered through Celite, and the solvent was removed under vacuum. The crude residue was chromatographed in 99:1 chloroform/methanol to provide 500 mg (34%) of the cyclized product as a white solid; mp 229–232 °C; IR (neat): 1649; ^1H NMR (CDCl_3) δ 1.58 (m, 6H), 2.38 (s, 6H), 2.99 (t, 2H, $J = 6.6$), 4.30 (m, 4H), 4.58 (t, 2H, $J = 6.6$), 6.16 (s, 2H), 7.43 (s, 1H), 7.63 (s, 1H), 7.85 (s, 1H), 9.31 (s, 1H); ^{13}C NMR (CDCl_3) δ 14.7, 14.7, 45.8, 49.1, 57.9, 64.7, 64.9, 101.2, 102.2, 103.2, 107.0, 109.8, 111.7, 114.8, 119.1, 127.3, 140.8, 143.5, 147.2, 147.6, 149.8, 149.9, 153.8, 164.1; HRMS m/z Calcd for $\text{C}_{29}\text{H}_{27}\text{O}_5\text{N}_3$: 450.2029; found: 450.2030.

4.9. Topoisomerase-mediated DNA cleavage assays

Human topoisomerase I was expressed in *Escherichia coli* and isolated as a recombinant fusion protein using a T7 expression system as described previously.¹⁷ Plasmid YepG was also purified by the alkali lysis method followed by phenol deproteination and CsCl /ethidium isopycnic centrifugation method as described.¹⁸ The 3' endlabeling of the plasmid was accomplished by digestion with a restriction enzyme followed by end filling with Klenow

polymerase as previously described.¹⁹ The cleavage assays were performed as previously reported.^{20,21} The drug and the DNA in presence of topoisomerase I was incubated for 30 min at room temperature. The reactions were terminated by the addition of 5 μ L of 5% SDS and 1 mg/mL protein kinase K with an additional 1 h of incubation at 37 °C. Samples were then alkali denatured by the addition of NaOH, EDTA, sucrose, and bromophenol blue to final concentrations of 75 mM, 2.5%, and 0.05 mg/mL, respectively, prior to loading onto a neutral agarose gel. After development of the gels, typically 24-h exposure was used to obtain autoradiograms outlining the extent of DNA fragmentation. Topoisomerase I-mediated DNA cleavage values are reported as relative effective concentration (REC), that is, concentrations relative to camptothecin, whose value is arbitrarily assumed as 0.2, that are able to produce the same 10% cleavage on the plasmid DNA in the presence of human topoisomerase I.

4.10. Cytotoxicity assays

The cytotoxicity was determined using the MTT-microtiter plate tetrazolium cytotoxicity assay (MTA). The human lymphoblast RPMI 8402 and its camptothecin-resistant variant cell line, CPT-K5 was provided by Dr. Toshiwo Andoh (Aichi Cancer Center Research Institute, Nagoya, Japan).¹⁰ The P388 mouse leukemia cell line and its CPT-resistant TOP1-deficient variant P388/CPT45¹¹ were obtained from Michael R. Mattern and Randal K. Johnson (GlaxoSmithKline, King of Prussia, PA). The KB3-1 cell line and its multidrug-resistant variant KBV-1¹³ were obtained from K.V. Chin (The Cancer Institute of New Jersey, New Brunswick, NJ). The KBH5.0 cell line as noted previously⁸ was derived from KB3-1 by stepwise selection against Hoechst 33342. The cytotoxicity assay was performed using 96-well microtiter plates. Cells were grown in suspension at 37 °C in 5% CO₂ and maintained by regular passage in RPMI medium supplemented with 10% heat inactivated fetal bovine serum, L-glutamine (2 mM), penicillin (100 U/mL), and streptomycin (0.1 mg/mL). For determination of IC₅₀, cells were exposed continuously for four days to varying concentrations of drug, and MTT assays were performed at the end of the fourth day. Each assay was performed with a control that did not contain any drug. All assays were performed at least twice in six replicate wells.

4.11. Human tumor xenograft

Bioassays were performed using female NCR/NU NU mice of approximately 9 weeks of age as obtained from Taconic Farms, Inc. (Germantown, NY, USA). Mice were housed 4 per cage in laminar flow HEPA filtered microisolator caging (Allentown Caging Equipment Co., Allentown, NJ, USA) with two cages used per experimental group. Mice were fed Purina autoclavable breeder chow #5021 and given drinking water, purified by reverse-osmosis, ad libitum. Five days after arrival within the animal facility, the mice were inoculated on the right flank with 1.5×10^6 MDA-MB-435 tumor cells in 0.1 mL of RPMI 1640 Media by sc injection (25 gauge needle $\times$ 5/8"). The MDA-MB-435 cells were grown in 75 cm² flasks using RPMI 1640 Media and 10% fetal bovine serum. Tumors were of sufficient size at 19–20 days after inoculation. Tumor-bearing mice were evenly matched in each experimental group based on tumor volume. Tumor volume was calculated by measuring the tumor with a microcaliper. The length (l) is the maximum two dimensional distance of the tumor and the width (w) is the maximum distance perpendicular to this length measured in mm. Tumor volume was calculated using the formula ($l \times w^2$)/2. Every mouse in this study was weighed individually on a daily basis. Dose adjustments for each experimental group, as indicated in Table 3, were made throughout the study based upon the effect or lack of an effect of treatment on average body weights. Tumor volume was determined for each individual mouse every other day.

Acknowledgments

This study was supported by National Cancer Institute Grants CA098127 (E.J.L.) and CA39662 (L.F.L.) and Genzyme Corporation.

References and notes

1. Champoux JJ. *Annu Rev Biochem* 2001;70:369. [PubMed: 11395412]
2. Wang JC. *Nat Rev Mol Cell Biol* 2002;3:430. [PubMed: 12042765]
3. Chen AY, Liu LF. *Annu Rev Pharmacol Toxicol* 1994;34:191. [PubMed: 8042851]
4. Li TK, Liu LF. *Annu Rev Pharmacol Toxicol* 2001;41:53. [PubMed: 11264450]
5. Pommier Y. *Nat Rev Cancer* 2006;6:789. [PubMed: 16990856]
6. Ruchelman AL, Singh SK, Wu XH, Ray A, Yang JM, Li TK, Liu A, Liu LF, LaVoie EJ. *Bioorg Med Chem Lett* 2002;12:3333. [PubMed: 12392745]
7. Ruchelman AL, Singh SK, Ray A, Wu X, Yang JM, Li TK, Liu A, Liu LF, LaVoie EJ. *Bioorg Med Chem* 2003;11:2061. [PubMed: 12670657]
8. Li TK, Houghton PJ, Desai SD, Daroui P, Liu AA, Hars ES, Ruchelman AL, LaVoie EJ, Liu LF. *Cancer Res* 2003;63:8400. [PubMed: 14679002]
9. Ruchelman AL, Zhou N, Liu A, Liu LF, LaVoie EJ. *J Med Chem* 2005;48:792. [PubMed: 15689163]
10. Andoh T, Ishii K, Suzuki Y, Ikegami Y, Kusunoki Y, Takemoto Y, Okada K. *Proc Natl Acad Sci* 1987;84:5565. [PubMed: 3039492]
11. Woessner RD, Eng WK, Hofmann GA, Rieman DJ, McCabe FL, Hertzberg RP, Mattern MR, Tan KB, Johnson RK. *Oncol Res* 1992;4:481. [PubMed: 1338578]
12. Rajendra R, Gounder MK, Saleem A, Schellens JHM, Ross DD, Bates SE, Sinko P, Rubin EH. *Cancer Res* 2003;63:3228. [PubMed: 12810652]
13. Gervasoni JE Jr, Fields SZ, Krishna S, Baker MA, Rosado M, Thuraiamy K, Hindenburg AA, Taub RN. *Cancer Res* 1991;51:4955. [PubMed: 1680024]
14. Chen AY, Yu C, Potmesil M, Wall ME, Wani MC, Liu LF. *Cancer Res* 1991;51:6039. [PubMed: 1682041]
15. Kawabata S, Oka M, Shiozawa K, Tsukamoto K, Nakatomi K, Soda H, Fududa M, Ikegami Y, Sugahara K, Yamada Y, Kamihira S, Doyle LA, Ross DD, Kohno S. *Biochem Biophys Res Commun* 2001;280:1216. [PubMed: 11162657]
16. Yang CH, Schneider E, Kuo ML, Volk EL, Rocchi E, Chen YC. *Biochem Pharmacol* 2000;60:831. [PubMed: 10930538]
17. Makhey D, Yu C, Liu A, Liu LF, LaVoie EJ. *Bioorg Med Chem* 2000;8:1171. [PubMed: 10882027]
18. Maniatis, T.; Fritsch, EF.; Sambrook, J. *Molecular Cloning, A Laboratory Manual*. Cold Spring Harbor Laboratory; Cold Spring Harbor, NJ: 1982. p. 149-185.
19. Tewey KM, Rowe TC, Yang L, Hallogan BC, Liu LF. *Science* 1984;226:466. [PubMed: 6093249]
20. Gatto B, Sanders MM, Yu C, Wu HY, Makhey D, LaVoie EJ, Liu LF. *Cancer Res* 1996;56:2795. [PubMed: 8665516]
21. Wang H, Mao Y, Chen A, Zhou N, LaVoie EJ, Liu LF. *Biochemistry* 2001;40:3316. [PubMed: 11258951]

- 1** $\text{R} = \text{CH}_3$, ARC-111
2 $\text{R} = \text{CH}_2\text{CH}_3$
3 $\text{R} = \text{CH}(\text{CH}_3)_2$

Figure 1.
Structure of ARC-111 and related compounds.

Figure 2.
Antitumor activity of compounds **10**, **13**, **16**, vehicle, and ARC-111.

Figure 3.
Antitumor activity of compounds **8**, **11**, **14**, vehicle, and ARC-111.

Figure 4.
Antitumor activity of compounds **12** and **15**, vehicle, and ARC-111.

Scheme 1.
Preparation of 7-9, 10-12, and 13-15.

Scheme 2.
Preparation of **16**.

Scheme 3.
Preparation of **21**.

Table 1
 TOP1-targeting activity and cytotoxicity in RPMI8402 and P388 cells and their camptothecin-resistant variants

Compound	TOP1-mediated cleavage ^a	Cytotoxicity IC ₅₀ (μM)			
		RPMI8402	CPT-K5	P388	P388/CPT 45
1	0.3	0.002	0.90	0.001	0.23
7	>10	0.25	>10	0.25	>10
8	>10	0.7	>10	0.61	>10
9	>10	1.9	>10	1.1	>10
10	<0.2	0.004	0.98	0.003	0.22
11	<0.2	0.001	0.67	0.001	0.13
12	<0.2	0.002	1.3	0.002	0.06
13	0.1	0.008	4.5	0.02	0.4
14	>10	0.017	>10	0.035	2.3
15	>10	0.065	>10	0.08	3.7
16	0.3	0.003	3.5	0.009	0.39
21	>10	0.15	0.14	0.015	0.013
CPT	0.2	0.006	>10	0.014	>10
Topotecan	1.0	0.021	>10	0.045	>10

^aTopoisomerase I cleavage values are reported as REC, relative effective concentration. These are concentrations relative to topotecan, whose value is arbitrarily assumed as 1, that are able to produce 10% cleavage of the plasmid DNA in the presence of human topoisomerase I.

Table 2

Cytotoxicity of N-substituted 5-[2-(*N*-alkylamino)ethyl]dibenzo[*c,h*][1,6]naphthyridines in KB3-1 cells and its variant cell lines, KBV-1 and KBH5.0

Compound	Cytotoxicity IC ₅₀ (μM)		
	KB3-1	KBV-1	KBH5.0
1	0.005	0.005	0.006
7	0.41	1.0	0.63
8	0.65	2.9	0.75
9	1.0	4.4	1.1
10	0.005	0.043	0.027
11	0.004	0.034	0.007
12	0.006	0.043	0.009
13	0.02	0.07	0.034
14	0.07	0.1	0.11
15	0.10	0.43	0.07
16	0.01	0.38	0.32
21	0.07	0.19	0.1
Topotecan	0.04	0.44	0.44

Table 3
Antitumor activity in athymic nude mice with the human tumor xenograft MDA-MB-435

Compound	Route	Average tumor volume (mm ³)							Total dose (mg/kg)/mouse
		Day 7	Day 14	Day 21	Day 28	Day 35	Day 42	Day 49	
8	I.P. ^a	127	176	268	310	435	543	718	111
10	I.P. ^a	149	222	370	392	528	669	919	111
11	I.P. ^a	100	156	178	202	293	361	435	117
12	I.P. ^b	142	175	213	220	250	286	314	168
13	I.P. ^c	144	167	218	284	317	358	433	223
14	I.P. ^a	115	106	170	204	331	349	488	117
15	I.P. ^a	99	112	165	170	234	310	357	117
16	I.P. ^d	147	178	230	319	344	434	527	301
Vehicle	I.P. ^e	126	181	332	408	573	747	966	
1	I.P. ^f	120	123	145	158	175	189	242	37.5

^aInitial dose was 2.0 mg/kg qd × 5/week for 2 weeks and was gradually increased to 6.0 mg/kg × 5/week.

^bInitial dose was 5.0 mg/kg qd × 5/week and was increased to 6.0 mg/kg qd × 5/week for 2 weeks, then adjusted to 6.0 mg/kg qd × 3/week for one week. This dose was then again modified to the initial dose of 5.0 mg/kg qd × 5/week.

^cInitial dose was 5.0 mg/kg qd × 5/week for 1 week and was gradually increased to 7.0 mg/kg × 5/week.

^dInitial dose was 5.0 mg/kg qd × 5/week for one and a half weeks and was increased to 6.0 mg/kg qd × 5/week for two and a half weeks. Administration was increased to 14.0 mg/kg qd × 5/week for one and a half weeks then adjusted back to 10.0 mg/kg qd × 5/week for 1 week and finally adjusted to 12.0 mg/kg qd × 5/week.

^eVehicle consisted of 0.1% citrate in H₂O and was administered qd × 5/week.

^fInitial dose was 1.5 mg/kg, which was administered qd × 3/5 days.